Physician profile
Beth Howell
NPI 1689496283
$1,576.74
in general payments reported to CMS, 2019-2025
12 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $431 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $403.61 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $310.65 | 2024-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $294.96 | 2024-2025 | Rocklatan, Tryptyr, Clareon |
| Apellis Pharmaceuticals, INC. | $134.92 | 2025 | Syfovre |
| Sun Pharmaceutical Industries INC. | $120.26 | 2024-2025 | |
| Amgen INC. | $82.14 | 2025 | Tepezza |
| Genzyme Corporation | $77.06 | 2024 | |
| Dompe US, INC. | $63.42 | 2025 | Oxervate |
| Biogen, INC. | $25.22 | 2024 | Skyclarys |
| Sight Sciences, INC. | $24.32 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Oyster Point Pharma, INC. | $20.27 | 2025 | Ryzumvi, Tyrvaya |
| Harrow Eye, LLC | $19.91 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.